Novo Nordisk A/S ADR (NVO)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
| 03-2017 | 12-2016 | 09-2016 | 06-2016 | 03-2016 | |
| Sales | 4,080,017 | 4,284,281 | 4,130,550 | 4,171,022 | 4,024,655 |
| Cost of Goods | 609,593 | 714,850 | 597,900 | 614,436 | 626,209 |
| Gross Profit | 3,470,423 | 3,569,432 | 3,532,650 | 3,556,587 | 3,398,446 |
| Operating Expenses | 1,536,551 | 1,955,081 | 1,670,550 | 1,658,728 | 1,578,154 |
| Operating Income | 1,934,466 | 1,615,200 | 1,863,000 | 1,898,294 | 1,820,501 |
| Interest Expense | 106,690 | 36,252 | 17,400 | -1,823 | 56,054 |
| Other Income | 36,998 | -3,408 | -450 | 14,127 | 3,402 |
| Pre-tax Income | 1,864,774 | 1,575,540 | 1,845,150 | 1,914,244 | 1,767,849 |
| Income Tax | 408,403 | 322,869 | 374,700 | 400,105 | 369,454 |
| Net Income Continuous | 1,456,370 | 1,252,671 | 1,470,450 | 1,514,139 | 1,398,395 |
| Net Income | $1,456,370 | $1,252,671 | $1,470,450 | $1,514,139 | $1,398,395 |
| EPS Basic Total Ops | 0.29 | 0.25 | 0.29 | 0.30 | 0.28 |
| EPS Basic Continuous Ops | 0.29 | 0.25 | 0.29 | 0.30 | 0.27 |
| EPS Diluted Total Ops | 0.29 | 0.25 | 0.29 | 0.30 | 0.27 |
| EPS Diluted Continuous Ops | 0.29 | 0.25 | 0.29 | 0.30 | 0.27 |
| EBITDA(a) | $2,035,993 | $1,778,129 | $1,970,852 | $2,009,702 | $1,912,791 |